Aristotle Capital Management LLC Reduces Stock Position in Roche Holding AG $RHHBY

Key Points

• Aristotle Capital trimmed its stake in Roche by 1.2% in Q3, selling 27,323 shares and leaving it with 2,178,682 ADRs worth about $90.44 million.
• Analyst coverage is mixed but leans neutral: the stock has an average rating of "Hold" with an average price target of $57.00, after several recent upgrades and reaffirmations.
• Roche ADRs opened at $50.12 and were down about 3.5%, trading below the 50‑day moving average ($56.04) but near the 200‑day average ($49.06), inside a 12‑month range of $34.75–$60.85.

Aristotle Capital Management LLC cut its holdings in Roche Holding AG (OTCMKTS:RHHBY - Free Report) by 1.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,178,682 shares of the company's stock after selling 27,323 shares during the quarter. Aristotle Capital Management LLC's holdings in Roche were worth $90,444,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of RHHBY. Boston Common Asset Management LLC raised its position in Roche by 1.9% during the 3rd quarter. Boston Common Asset Management LLC now owns 368,553 shares of the company's stock valued at $15,049,000 after purchasing an additional 6,720 shares during the last quarter. Altrius Capital Management Inc grew its position in shares of Roche by 4.0% in the 3rd quarter. Altrius Capital Management Inc now owns 198,278 shares of the company's stock worth $8,290,000 after buying an additional 7,659 shares during the last quarter. Bard Financial Services Inc. grew its position in shares of Roche by 1.3% in the 3rd quarter. Bard Financial Services Inc. now owns 138,650 shares of the company's stock worth $5,797,000 after buying an additional 1,800 shares during the last quarter. Rhumbline Advisers increased its stake in shares of Roche by 1.1% during the second quarter. Rhumbline Advisers now owns 108,480 shares of the company's stock valued at $4,422,000 after buying an additional 1,228 shares during the period. Finally, Diversified Trust Co raised its holdings in shares of Roche by 0.5% during the third quarter. Diversified Trust Co now owns 57,881 shares of the company's stock valued at $2,363,000 after acquiring an additional 310 shares in the last quarter.

Wall Street Analysts Forecast Growth

RHHBY has been the subject of a number of research analyst reports. TD Cowen reaffirmed a "hold" rating on shares of Roche in a research note on Tuesday, February 10th. JPMorgan Chase & Co. upgraded shares of Roche from an "underweight" rating to a "neutral" rating in a report on Monday, December 8th. Barclays raised shares of Roche from an "equal weight" rating to an "overweight" rating in a research report on Tuesday, January 6th. Morgan Stanley reaffirmed an "underweight" rating on shares of Roche in a research note on Wednesday, February 4th. Finally, The Goldman Sachs Group upgraded shares of Roche from a "sell" rating to a "hold" rating in a research report on Thursday, January 15th. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $57.00.

Roche Stock Down 3.5%

Shares of RHHBY stock opened at $50.12 on Friday. The business's fifty day moving average is $56.04 and its 200 day moving average is $49.06. The company has a quick ratio of 1.12, a current ratio of 1.38 and a debt-to-equity ratio of 0.72. Roche Holding AG has a twelve month low of $34.75 and a twelve month high of $60.85.

Roche Profile

Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann‑La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY OTCMKTS: RHHBY.

In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.